AMLX - NASDAQ
Amylyx Pharmaceuticals, Inc.
$13.20
-0.68%Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotAmylyx Pharmaceuticals, Inc. Management Team
Mr. James M. Frates M.B.A.
Chief Financial Officer
Compensation
$806,277
Ms. Linda A. Arsenault
Chief Human Resources Officer
Ms. Gina M. Mazzariello J.D.
Chief Legal Officer & General Counsel
Compensation
$715,494
Mr. Tom Holmes
Chief Technical Operations Officer
Mr. Joshua B. Cohen
Co-Founder, Co-Chief Executive Officer & Director
Compensation
$1,225,305
Mr. Justin B. Klee
Co-Founder, Co-Chief Executive Officer & Director
Compensation
$1,225,305
Ms. Tammy Sarnelli
Global Head of Regulatory Affairs
Dr. Jamie Timmons
Head of Global Medical Strategy & Communications
Ms. Lindsey Allen
Head of Investor Relations & Communications
Dr. Machelle Manuel Ph.D.
Vice President & Head of Global Medical Affairs
Amylyx Pharmaceuticals, Inc. Insider Positioning
During the last 12 months, insiders have purchased $152K and sold $6.25M worth of AMLX shares, resulting in $6.10M of net selling activity.
3 Months
3.8K
51.34K
0
0.00
+51K
+$51K
3-6 Months
8.1K
100.84K
416.3K
5.73M
-5.6M
-$5.63M
6-9 Months
0
0.00
36.4K
522.37K
-522K
-$522K
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Firestone Karen
Director
$152K
Top Sellers
Klee Justin B.
Director, Officer: Co-Chief Executive Officer
$3.04M
Cohen Joshua B
Director, Officer: Co-Chief Executive Officer
$2.62M
Frates James M
Officer: Chief Financial Officer
$204K
Mazzariello Gina
Officer: Chief Legal Officer
$198K
Bedrosian Camille L
Officer: Chief Medical Officer
$189K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $6.10M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
5 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
SEC Filings
AMLX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 23, 2026 | June 04, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 24, 2025 | June 05, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 24, 2024 | June 06, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 27, 2023 | June 08, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 29, 2022 | June 09, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.